{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:24:47Z","timestamp":1794410687822,"version":"4.9.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:00:00Z","timestamp":1697241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI136831"],"award-info":[{"award-number":["AI136831"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI145539"],"award-info":[{"award-number":["AI145539"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1P30AI168439"],"award-info":[{"award-number":["1P30AI168439"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012403","name":"Texas Biomedical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012403","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.biopha.2023.115738","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T07:06:29Z","timestamp":1697699189000},"page":"115738","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Combination of MCL-1 and BCL-2 inhibitors is a promising approach for a host-directed therapy for tuberculosis"],"prefix":"10.1016","volume":"168","author":[{"given":"Eusondia","family":"Arnett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanta","family":"Pahari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrissy M.","family":"Leopold Wager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan R.","family":"Bonifacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7200-5826","authenticated-orcid":false,"given":"Miranda","family":"Lumbreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Renshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Montoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph T.","family":"Opferman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry S.","family":"Schlesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.115738_bib1","series-title":"Global Tuberculosis Report","author":"WHO","year":"2022"},{"issue":"7470","key":"10.1016\/j.biopha.2023.115738_bib2","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/502S2a","article-title":"Epidemiology: A mortal foe","volume":"502","author":"Paulson","year":"2013","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.biopha.2023.115738_bib3","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/infdis\/jiy712","article-title":"Remembering the host in tuberculosis drug development","volume":"219","author":"Frank","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.biopha.2023.115738_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2022.101672","article-title":"Inflammation-mediated tissue damage in pulmonary tuberculosis and host-directed therapeutic strategies","volume":"65","author":"Tiwari","year":"2023","journal-title":"Semin Immunol."},{"key":"10.1016\/j.biopha.2023.115738_bib5","first-page":"1","article-title":"Host-directed immunotherapy of viral and bacterial infections: past, present and future","author":"Wallis","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.biopha.2023.115738_bib6","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.immuni.2021.07.010","article-title":"Live and let die: TB control by enhancing apoptosis","volume":"54","author":"Arnett","year":"2021","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.biopha.2023.115738_bib7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.smim.2014.10.001","article-title":"Cell death and autophagy in tuberculosis","volume":"26","author":"Moraco","year":"2014","journal-title":"Semin Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2023.115738_bib8","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1084\/jem.20181776","article-title":"A major role for ferroptosis in Mycobacterium tuberculosis-induced cell death and tissue necrosis","volume":"216","author":"Amaral","year":"2019","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.biopha.2023.115738_bib9","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1128\/iai.65.1.298-304.1997","article-title":"Infection by Mycobacterium tuberculosis promotes human alveolar macrophage apoptosis","volume":"65","author":"Keane","year":"1997","journal-title":"Infect. Immun."},{"issue":"8","key":"10.1016\/j.biopha.2023.115738_bib10","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.immuni.2021.06.009","article-title":"Macrophage and neutrophil death programs differentially confer resistance to tuberculosis","volume":"54","author":"Stutz","year":"2021","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.biopha.2023.115738_bib11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41568-021-00407-4","article-title":"The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs","volume":"22","author":"Diepstraten","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2023.115738_bib12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","article-title":"Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins","volume":"20","author":"Singh","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.biopha.2023.115738_bib13","doi-asserted-by":"crossref","first-page":"334","DOI":"10.5483\/BMBRep.2008.41.4.334","article-title":"Common MCL1 polymorphisms associated with risk of tuberculosis","volume":"41","author":"Shin","year":"2008","journal-title":"BMB Rep."},{"key":"10.1016\/j.biopha.2023.115738_bib14","doi-asserted-by":"crossref","DOI":"10.1590\/s1678-9946202264059","article-title":"Polymorphisms of the BCL2 gene associated with susceptibility to tuberculosis","volume":"64","author":"He","year":"2022","journal-title":"Rev. Inst. Med Trop. Sao Paulo"},{"issue":"6","key":"10.1016\/j.biopha.2023.115738_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007100","article-title":"PPARgamma is critical for Mycobacterium tuberculosis induction of Mcl-1 and limitation of human macrophage apoptosis","volume":"14","author":"Arnett","year":"2018","journal-title":"PLoS Pathog."},{"issue":"22","key":"10.1016\/j.biopha.2023.115738_bib16","doi-asserted-by":"crossref","first-page":"13762","DOI":"10.1021\/acs.jmedchem.0c01234","article-title":"Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor","volume":"63","author":"Szlavik","year":"2020","journal-title":"J. Med Chem."},{"issue":"1","key":"10.1016\/j.biopha.2023.115738_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9","author":"Tron","year":"2018","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.biopha.2023.115738_bib18","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","article-title":"AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies","volume":"8","author":"Caenepeel","year":"2018","journal-title":"Cancer Discov."},{"issue":"7626","key":"10.1016\/j.biopha.2023.115738_bib19","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2023.115738_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02537-14","article-title":"Characterization of host and microbial determinants in individuals with latent tuberculosis infection using a human granuloma model","volume":"6","author":"Guirado","year":"2015","journal-title":"MBio"},{"issue":"8","key":"10.1016\/j.biopha.2023.115738_bib21","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00131-17","article-title":"The mycobacterium tuberculosis mmpl11 cell wall lipid transporter is important for biofilm formation, intracellular growth, and nonreplicating persistence","volume":"85","author":"Wright","year":"2017","journal-title":"Infect. Immun."},{"issue":"12","key":"10.1016\/j.biopha.2023.115738_bib22","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1093\/infdis\/jiz020","article-title":"In vitro granuloma models of tuberculosis: potential and challenges","volume":"219","author":"Elkington","year":"2019","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.biopha.2023.115738_bib23","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1165\/rcmb.2016-0321OC","article-title":"A novel in vitro human granuloma model of sarcoidosis and latent tuberculosis infection","volume":"57","author":"Crouser","year":"2017","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115738_bib24","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1165\/rcmb.2018-0053OC","article-title":"IL-13-regulated macrophage polarization during granuloma formation in an in vitro human sarcoidosis model","volume":"60","author":"Locke","year":"2019","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.biopha.2023.115738_bib25","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1172\/JCI114568","article-title":"Phagocytosis of leprosy bacilli is mediated by complement receptors CR1 and CR3 on human monocytes and complement component C3 in serum","volume":"85","author":"Schlesinger","year":"1990","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.biopha.2023.115738_bib26","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.4049\/jimmunol.150.7.2920","article-title":"Macrophage phagocytosis of virulent but not attenuated strains of Mycobacterium tuberculosis is mediated by mannose receptors in addition to complement receptors","volume":"150","author":"Schlesinger","year":"1993","journal-title":"J. Immunol."},{"issue":"14","key":"10.1016\/j.biopha.2023.115738_bib27","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1182\/blood.2020006916","article-title":"Requirement for antiapoptotic MCL-1 during early erythropoiesis","volume":"137","author":"Turnis","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.biopha.2023.115738_bib28","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1462-5822.2010.01563.x","article-title":"Defensins enable macrophages to inhibit the intracellular proliferation of Listeria monocytogenes","volume":"13","author":"Arnett","year":"2011","journal-title":"Cell Microbiol"},{"issue":"9","key":"10.1016\/j.biopha.2023.115738_bib29","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.bmc.2015.03.041","article-title":"Design and synthesis of novel anti-tuberculosis agents from the celecoxib pharmacophore","volume":"23","author":"Salunke","year":"2015","journal-title":"Bioorg. Med Chem."},{"issue":"10","key":"10.1016\/j.biopha.2023.115738_bib30","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1128\/AAC.00830-09","article-title":"Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis","volume":"53","author":"Almeida","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.biopha.2023.115738_bib31","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.4049\/jimmunol.144.7.2771","article-title":"Phagocytosis of mycobacterium-tuberculosis is mediated by human monocyte complement receptors and complement component-C3","volume":"144","author":"Schlesinger","year":"1990","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2023.115738_bib32","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.4049\/jimmunol.147.6.1983","volume":"147","author":"Schlesinger","year":"1991","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.biopha.2023.115738_bib33","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1128\/IAI.68.10.5619-5627.2000","article-title":"Gallium disrupts iron metabolism of mycobacteria residing within human macrophages","volume":"68","author":"Olakanmi","year":"2000","journal-title":"Infect. Immun."},{"issue":"1","key":"10.1016\/j.biopha.2023.115738_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.561","article-title":"Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)","volume":"6","author":"Leverson","year":"2015","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.biopha.2023.115738_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-019-1568-3","article-title":"BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival","volume":"10","author":"Lee","year":"2019","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.biopha.2023.115738_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-020-2646-2","article-title":"MCL1 inhibitors S63845\/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells","volume":"11","author":"Mukherjee","year":"2020","journal-title":"Cell Death Dis."},{"issue":"8","key":"10.1016\/j.biopha.2023.115738_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082182","article-title":"Simultaneously inhibiting BCL2 and MCL1 Is a therapeutic option for patients with advanced melanoma","volume":"12","author":"Mukherjee","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.biopha.2023.115738_bib38","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med"},{"issue":"2","key":"10.1016\/j.biopha.2023.115738_bib39","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41418-022-01060-6","article-title":"Dying in self-defence: a comparative overview of immunogenic cell death signalling in animals and plants","volume":"30","author":"Maekawa","year":"2023","journal-title":"Cell Death Differ."},{"issue":"8","key":"10.1016\/j.biopha.2023.115738_bib40","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/ni.1758","article-title":"Mycobacterium tuberculosis evades macrophage defenses by inhibiting plasma membrane repair","volume":"10","author":"Divangahi","year":"2009","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2023.115738_bib41","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.chom.2012.06.010","article-title":"Efferocytosis is an innate antibacterial mechanism","volume":"12","author":"Martin","year":"2012","journal-title":"Cell Host. Microbe"},{"key":"10.1016\/j.biopha.2023.115738_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.574338","article-title":"The Multifaceted Roles of the BCL-2 Family Member BOK","volume":"8","author":"Naim","year":"2020","journal-title":"Front Cell Dev. Biol."},{"issue":"6","key":"10.1016\/j.biopha.2023.115738_bib43","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/s41385-018-0071-y","article-title":"A novel role for C-C motif chemokine receptor 2 during infection with hypervirulent Mycobacterium tuberculosis","volume":"11","author":"Dunlap","year":"2018","journal-title":"Mucosal Immunol."},{"issue":"10","key":"10.1016\/j.biopha.2023.115738_bib44","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s41564-018-0245-0","article-title":"Mycobacterium tuberculosis carrying a rifampicin drug resistance mutation reprograms macrophage metabolism through cell wall lipid changes","volume":"3","author":"Howard","year":"2018","journal-title":"Nat. Microbiol"},{"issue":"10202","key":"10.1016\/j.biopha.2023.115738_bib45","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0140-6736(19)31882-3","article-title":"Management of drug-resistant tuberculosis","volume":"394","author":"Lange","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.biopha.2023.115738_bib46","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S1473-3099(21)00808-2","article-title":"25 years of surveillance of drug-resistant tuberculosis: achievements, challenges, and way forward","volume":"22","author":"Dean","year":"2022","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2023.115738_bib47","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1128\/AAC.47.1.360-362.2003","article-title":"Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB\/c mice","volume":"47","author":"Fattorini","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/j.biopha.2023.115738_bib48","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/nm.3937","article-title":"The association between sterilizing activity and drug distribution into tuberculosis lesions","volume":"21","author":"Prideaux","year":"2015","journal-title":"Nat. Med"},{"issue":"3","key":"10.1016\/j.biopha.2023.115738_bib49","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00159-19","article-title":"Caseum: a niche for mycobacterium tuberculosis drug-tolerant persisters","volume":"33","author":"Sarathy","year":"2020","journal-title":"Clin. Microbiol Rev."},{"issue":"3","key":"10.1016\/j.biopha.2023.115738_bib50","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1055\/s-0038-1661383","article-title":"Management of multidrug-resistant tuberculosis","volume":"39","author":"Daley","year":"2018","journal-title":"Semin Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.biopha.2023.115738_bib51","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00312-17","article-title":"Digitally barcoding mycobacterium tuberculosis reveals in vivo infection dynamics in the macaque model of tuberculosis","volume":"8","author":"Martin","year":"2017","journal-title":"mBio"},{"issue":"1","key":"10.1016\/j.biopha.2023.115738_bib52","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02073-16","article-title":"A bioengineered three-dimensional cell culture platform integrated with microfluidics to address antimicrobial resistance in tuberculosis","volume":"8","author":"Bielecka","year":"2017","journal-title":"mBio"},{"issue":"7","key":"10.1016\/j.biopha.2023.115738_bib53","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1242\/dmm.016089","article-title":"Fit for consumption: zebrafish as a model for tuberculosis","volume":"7","author":"Cronan","year":"2014","journal-title":"Dis. Model Mech."},{"issue":"3","key":"10.1016\/j.biopha.2023.115738_bib54","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cell.2013.03.022","article-title":"TNF dually mediates resistance and susceptibility to mycobacteria via mitochondrial reactive oxygen species","volume":"153","author":"Roca","year":"2013","journal-title":"Cell"},{"issue":"10181","key":"10.1016\/j.biopha.2023.115738_bib55","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/S0140-6736(19)30308-3","article-title":"Tuberculosis","volume":"393","author":"Furin","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.biopha.2023.115738_bib56","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S2213-2600(19)30263-2","article-title":"g. Lancet Respiratory Medicine drug-resistant tuberculosis Commission, The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis","volume":"7","author":"Dheda","year":"2019","journal-title":"Lancet Respir. Med"},{"issue":"5","key":"10.1016\/j.biopha.2023.115738_bib57","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3201\/eid2005.131037","article-title":"T.B.E.S. Consortium, Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007","volume":"20","author":"Marks","year":"2014","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.biopha.2023.115738_bib58","unstructured":"CDC, CDC fact sheets, 2022. \u3008https:\/\/www.cdc.gov\u3009."},{"issue":"11","key":"10.1016\/j.biopha.2023.115738_bib59","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.5588\/ijtld.22.0096","article-title":"Cost of TB services: approach and summary findings of a multi-country study (Value TB)","volume":"26","author":"Sweeney","year":"2022","journal-title":"Int J. Tube Lung Dis."},{"issue":"1","key":"10.1016\/j.biopha.2023.115738_bib60","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.chom.2011.11.012","article-title":"Mycobacterium tuberculosis inhibits neutrophil apoptosis, leading to delayed activation of naive CD4 T cells","volume":"11","author":"Blomgran","year":"2012","journal-title":"Cell Host Microbe"},{"issue":"6","key":"10.1016\/j.biopha.2023.115738_bib61","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ccell.2018.11.004","article-title":"BH3-mimetic drugs: blazing the trail for new cancer medicines","volume":"34","author":"Merino","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2023.115738_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100672","article-title":"Targeting MCL-1 in hematologic malignancies: rationale and progress","volume":"44","author":"Wei","year":"2020","journal-title":"Blood Rev."},{"issue":"9","key":"10.1016\/j.biopha.2023.115738_bib63","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.chembiol.2012.07.018","article-title":"A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival","volume":"19","author":"Cohen","year":"2012","journal-title":"Chem. Biol."},{"issue":"12","key":"10.1016\/j.biopha.2023.115738_bib64","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1182\/bloodadvances.2019001416","article-title":"Cotargeting BCL-2 and MCL-1 in high-risk B-ALL","volume":"4","author":"Moujalled","year":"2020","journal-title":"Blood Adv."},{"issue":"14","key":"10.1016\/j.biopha.2023.115738_bib65","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1158\/1078-0432.CCR-18-3275","article-title":"Cotargeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma","volume":"25","author":"Prukova","year":"2019","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.biopha.2023.115738_bib66","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3324\/haematol.2020.260331","article-title":"Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition","volume":"107","author":"Carter","year":"2022","journal-title":"Haematologica"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223015366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223015366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:21:56Z","timestamp":1779916916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223015366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":66,"alternative-id":["S0753332223015366"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115738","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of MCL-1 and BCL-2 inhibitors is a promising approach for a host-directed therapy for tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115738","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115738"}}